Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LPAR3 | Q9UBY5 | 15/20 | 0.55 |
| ▸ | LPAR2 | Q9HBW0 | 9/20 | 0.55 |
| ▸ | LPAR1 | Q92633 | 8/20 | 0.41 |
| ▸ | TSHR | P16473 | 1/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.34 |
| ▸ | LMNA | P02545 | 1/20 | 0.34 |
| ▸ | P2RY10 | O00398 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL53516 | 1.00 | LPAR3 (0.55) | LPAR3LPAR2LPAR1TSHRALDH1A1 | |
| SCHEMBL53103 | 1.00 | LPAR3 (0.55) | LPAR3LPAR2LPAR1TSHRALDH1A1 | |
| SCHEMBL52928 | 1.00 | LPAR3 (0.55) | LPAR3LPAR2LPAR1TSHRALDH1A1 | |
| SCHEMBL52988 | 1.00 | LPAR3 (0.55) | LPAR3LPAR2LPAR1TSHRALDH1A1 | |
| SCHEMBL54021 | 1.00 | LPAR3 (0.55) | LPAR3LPAR2LPAR1TSHRALDH1A1 | |
| SCHEMBL52964 | 1.00 | LPAR3 (0.55) | LPAR3LPAR2LPAR1TSHRALDH1A1 | |
| SCHEMBL52947 | 1.00 | LPAR3 (0.55) | LPAR3LPAR2LPAR1TSHRALDH1A1 | |
| SCHEMBL53597 | 0.96 | LPAR3 (0.51) | LPAR3LPAR2LPAR1LMNAP2RY10 | |
| SCHEMBL6429344 | 0.96 | LPAR3 (0.51) | LPAR3LPAR2LPAR1LMNAP2RY10 | |
| SCHEMBL54863 | 0.96 | LPAR3 (0.51) | LPAR3LPAR2LPAR1LMNAP2RY10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8129552-B2 | for transporting drugs or as gene transport vehicles, as solubilizers for drugs of low solubility in water, and themselves as active ingredients against diseases such as cancer or leishmaniosis; (Z)-6-octadecenyl-1-phospho-N,N,N-trimethylpropylammonium | MAX-PLANCK-GESELLSCHAFT ZUR FORDERUNG DER WISSENSCHAFTEN E.V. (DE) | 2012-03-06 | — | — | US | disclosed |
| US-20080214849-A1 | PHOSPHOLIPIDS WITH UNSATURATED ALKYL AND ACYL CHAINS | MAX-PLANCK-GESELLSCHAFT ZUR FOERDERUNG DER WISSENSHAFTEN E.V. (DE) | 2008-09-04 | — | — | US | disclosed |
| EP-1102775-B1 | NOVEL PHOSPHOLIPIDS WITH UNSATURATED ALKYL AND ACYL CHAINS | MAX PLANCK GESELLSCHAFT (DE) | 2005-06-08 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080214849-A1 | PHOSPHOLIPIDS WITH UNSATURATED ALKYL AND ACYL CHAINS | PHOSPHO1, PLTP, SGMS1 | LPAR3 55/4885LPAR2 53/4885LPAR1 48/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.